InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

Rhea-AI Summary

InflaRx (Nasdaq: IFRX) will participate in the Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026, with a fireside chat on March 9 at 9:20 AM ET and one-on-one investor meetings the same day.

Live streaming and replay of the fireside chat will be available via a company link; investor relations contacts are provided for meeting requests.

Key Figures

Conference dates: March 8–11, 2026 Fireside chat time: March 9, 9:20 AM ET Company founded: 2007

3 metrics

Conference dates March 8–11, 2026 Leerink Partners Global Healthcare Conference in Miami, FL

Fireside chat time March 9, 9:20 AM ET Scheduled conference fireside chat with InflaRx

Company founded 2007 Year InflaRx was founded

Market Reality Check

Price: $0.9336 Vol: Volume 337504 is close to...

normal vol

$0.9336 Last Close

Volume Volume 337504 is close to 20-day average 350797 (relative 0.96x), suggesting no unusual trading ahead of the conference. normal

Technical Shares trade below the 200-day MA at 1.11, sitting 51.88% below the 52-week high and 31.25% above the 52-week low.

Peers on Argus

IFRX was up 5.86% while key biotech peers were mixed: STTK -6.47%, SRZN -0.48%, ...

IFRX was up 5.86% while key biotech peers were mixed: STTK -6.47%, SRZN -0.48%, HLVX -0.48%, MGNX +10.98%, XBIT +0.85%. The varied moves point to stock-specific factors rather than a broad sector shift.

Historical Context

5 past events · Latest: Jan 29 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 29	Investor conferences	Neutral	+1.3%	Announcement of multiple February investor conference appearances and meetings.
Jan 08	Strategy shift	Negative	-9.2%	Cost-cutting, ~30% workforce reduction, and focus on izicopan with extended cash runway.
Dec 30	Phase 3 update	Negative	+0.0%	Terminated vilobelimab Phase 3 PG trial with mixed efficacy and post-hoc analyses.
Dec 11	Drug naming, data	Positive	-2.9%	WHO INN ‘izicopan’ plus supportive PK/PD and early efficacy signals for INF904.
Nov 10	Phase 2a results	Positive	+28.5%	Positive topline Phase 2a data for INF904 in HS and CSU with strong signals.

Pattern Detected

Stock reactions have been strongest on clear clinical data, with restructuring and naming updates producing more modest or mixed moves.

Recent Company History

Over the past few months, IFRX updates have centered on izicopan and vilobelimab. Positive Phase 2a data on INF904 in HS and CSU on Nov 10, 2025 coincided with a strong 28.46% gain, while later INN naming for izicopan on Dec 11, 2025 saw a modest -2.86% move. A terminated vilobelimab Phase 3 PG study update on Dec 30, 2025 had a flat reaction. The January 2026 cost-cutting and refocus on izicopan led to a -9.17% drop, whereas routine conference participation news in late January produced only a mild 1.3% uptick.

Market Pulse Summary

This announcement highlights InflaRx’s visibility efforts through a fireside chat on March 9 at the ...

Analysis

This announcement highlights InflaRx’s visibility efforts through a fireside chat on March 9 at the Leerink Partners Global Healthcare Conference and one-on-one investor meetings. It reinforces the company’s positioning around C5a and C5aR-targeted therapies, including lead program izicopan and antibody vilobelimab. In context of prior clinical data and recent strategic refocus, investors may watch for any incremental disclosures around trial plans, partnering progress, and capital-efficient development during these conference interactions.

Key Terms

complement system, c5a, c5ar, monoclonal antibody, +2 more

6 terms

complement system medical

"pioneering anti-inflammatory therapeutics by targeting the complement system, today announced"

The complement system is a set of proteins in the blood that act together like a security alarm and cleanup crew for the body’s immune system: they detect threats, tag invaders for removal, and help destroy harmful cells. Investors should care because drugs or diagnostics that target or measure this system can affect treatment effectiveness, safety profiles, and market potential for therapies in immune, inflammatory, and rare disease areas.

c5a medical

"specific inhibitors of the complement activation factor C5a and its receptor, C5aR."

C5a is a small protein produced by the immune system that acts like an alarm bell, signaling and attracting immune cells to sites of infection or injury and triggering inflammation. Investors care because excessive or uncontrolled C5a activity is linked to many inflammatory and autoimmune diseases, making it a common target for drugs and diagnostics; treatments that block or measure C5a can affect clinical outcomes, regulatory approval prospects, and commercial value in biotech and pharmaceutical portfolios.

c5ar medical

"anti-C5a and anti-C5aR technologies to discover, develop and commercialize"

C5aR is a protein on the surface of immune cells that senses and responds to a small immune signaling molecule called C5a; when activated it acts like a doorbell that calls immune cells and ramps up inflammation. It matters to investors because drugs that block or modulate this receptor can reduce harmful inflammation in diseases, so clinical trial results, approvals, or setbacks for C5aR-targeting therapies can materially affect a biotech’s value and market prospects.

monoclonal antibody medical

"vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

phase 1 medical

"therapeutic potential in Phase 1 and Phase 2a clinical studies."

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2a medical

"therapeutic potential in Phase 1 and Phase 2a clinical studies."

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

AI-generated analysis. Not financial advice.

JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows:

Leerink Partners Global Healthcare Conference
March 8 - 11, 2026 in Miami, FL
Fireside chat on March 9 at 9:20 AM ET

InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside chat live stream and its replay is available here.

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

When will InflaRx (IFRX) present at the Leerink Partners Global Healthcare Conference?

InflaRx will present a fireside chat on March 9, 2026 at 9:20 AM ET. According to InflaRx, the company will also hold one-on-one investor meetings on March 9 during the March 8-11, 2026 conference in Miami.

How can investors watch InflaRx's (IFRX) fireside chat from the March 2026 Leerink conference?

Investors can view a live stream and replay via a company-provided link. According to InflaRx, the fireside chat will be accessible live and as a replay through the link the company made available to investors.

Will InflaRx (IFRX) hold investor meetings at the March 2026 Leerink Partners conference?

Yes. InflaRx will conduct one-on-one investor meetings on March 9, 2026. According to InflaRx, investors should contact investor relations to request meetings during the Miami conference taking place March 8-11, 2026.

What topics might InflaRx (IFRX) cover in its March 9, 2026 fireside chat?

The fireside chat will likely cover InflaRx's anti-inflammatory programs and corporate overview. According to InflaRx, the company focuses on anti-C5a and anti-C5aR technologies and will discuss its lead programs and clinical development strategy.

Who should investors contact to schedule a meeting with InflaRx (IFRX) at the Leerink conference?

Investors should contact InflaRx investor relations or MC Services AG for meeting requests. According to InflaRx, IR contact details and MC Services AG email and phone numbers are provided for scheduling one-on-one meetings on March 9, 2026.